The Asia Pacific dPCR and qPCR market was valued at US$ 1,913.43 million in 2022 and is expected to reach US$ 4,139.50 million by 2030; it is estimated to grow at a CAGR of 10.1% from 2022 to 2030.
Technological Advancements in PCR Technologies Drive Asia Pacific dPCR and qPCR Market
Polymerase chain reaction (PCR) is a nearly ubiquitous, robust, and reliable technology used in most molecular biology labs to amplify specific stretches of DNA for genotyping, cloning, and analysis of single nucleotide variations and even serves as the basis for most next-generation sequencing (NGS) preparation. Technological advances are yielding different types of PCR techniques. The use of PCR technology has now been explored into several non-conventional applications, making molecular diagnosis easier and faster. In particular, advances in digital and real-time PCR are used to diagnose diseases, identify viruses and bacteria, and aid forensic investigations. Moreover, the researchers are trying to reduce test time using some nanomaterials. In March 2023, the Center for Augmented Safety System with Intelligence, Sensing of the Korea Institute of Science and Technology (KIST, President: Seok Jin Yoon) announced the development of an ultrafast PCR technology by Dr. Sang Kyung Kim (Director) and Dr. Seungwon Jung's research team. The ultrafast PCR reduces the test duration by ten times compared to the previous test by utilizing photothermal nanomaterials. The diagnostic performance of the new method is comparable to the current test method, and it can be finished in 5 minutes. Thus, technological advancements in PCR technologies propel the Asia Pacific dPCR and qPCR market growth.
Asia Pacific dPCR and qPCR Market Overview
The Asia Pacific dPCR and qPCR market in Asia Pacific is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China, India and Japan are three major contributors to the growth of the market which is driven by increasing foreign direct investments in these countries, highly skilled, efficient and large number of labor, and streamlining government policies resulting in high investments for biotechnology sector. In addition, increasing cases of infectious and chronic diseases and government and non-government initiatives are also responsible for fueling the growth of the Asia Pacific dPCR and qPCR market.
Asia Pacific dPCR and qPCR Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific dPCR and qPCR Market Segmentation
The Asia Pacific dPCR and qPCR market is segmented based on treatment, product, application, end user, and country.
Based on treatment, the Asia Pacific dPCR and qPCR market is bifurcated into quantitative PCR (qPCR) and digital PCR (dPCR). The digital PCR (dPCR) segment held a larger share in 2022.
By product, the Asia Pacific dPCR and qPCR market is segmented into reagents & consumables, instruments, and software & services. The reagents & consumables segment held the largest share in 2022.
By application, the Asia Pacific dPCR and qPCR market is research application, clinical application, and forensic application. The clinical application segment held the largest share in 2022. The clinical application segment is further subsegmented into oncology testing, blood screening, infectious disease testing, and other applications.
By end user, the Asia Pacific dPCR and qPCR market is segmented into hospitals and diagnostic centers, pharmaceutical and biotechnology companies, research laboratories and academic institutes, forensic laboratories, and clinical research organizations. The hospitals and diagnostic centers segment held the largest share in 2022.
Based on country, the Asia Pacific dPCR and qPCR market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific dPCR and qPCR market in 2022.
Abbott Laboratories, Thermo Fisher Scientific Inc, Takara Bio Inc, Genome Diagnostics Pvt Ltd, Qiagen NV, Standard BioTools Inc, Lepu Medical Technology Beijing Co Ltd, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, and Agilent Technologies Inc are some of the leading companies operating in the Asia Pacific dPCR and qPCR market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 1,913.43 Million |
| Market Size by 2030 | US$ 4,139.50 Million |
| CAGR (2022 - 2030) | 10.1% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Treatment
|
|
Regions and Countries Covered
|
|
| Asia-Pacific | China, India, Japan, Australia, Rest of Asia-Pacific |
| Market leaders and key company profiles |
|
1. Abbott Laboratories
2. Agilent Technologies Inc
3. Bio-Rad Laboratories Inc
4. F. Hoffmann-La Roche Ltd
5. Genome Diagnostics Pvt Ltd
6. Lepu Medical Technology Beijing Co Ltd
7. Qiagen NV
8. Standard BioTools Inc
9. Takara Bio Inc
10. Thermo Fisher Scientific Inc
The Asia Pacific dPCR and qPCR Market is valued at US$ 1,913.43 Million in 2022, it is projected to reach US$ 4,139.50 Million by 2030.
As per our report Asia Pacific dPCR and qPCR Market, the market size is valued at US$ 1,913.43 Million in 2022, projecting it to reach US$ 4,139.50 Million by 2030. This translates to a CAGR of approximately 10.1% during the forecast period.
The Asia Pacific dPCR and qPCR Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific dPCR and qPCR Market report:
The Asia Pacific dPCR and qPCR Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific dPCR and qPCR Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific dPCR and qPCR Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)